News
Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Media
Around the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsShortsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
Publications
All JournalsEditorial BoardFor AuthorsYear in Review
More
Events
Frontline ForumSatellite Sessions
CME/CE
Resources
Awareness MonthThe Bispecifics NetworkNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career Center

Subscribe

  • News
  • Media
  • Conferences
  • Publications
  • Events
  • CME/CE
  • Resources
  • Career Center
  • Subscribe
  • Adverse Effects
  • Artificial Intelligence
  • Brain Cancer
  • Breast Cancer
    • HER2-Positive Breast Cancer
    • Triple-Negative Breast Cancer
  • Gastrointestinal Cancer
    • Colorectal Cancer
    • Esophageal Cancer
    • Pancreatic Cancer
    • Gastric Cancer
    • Liver Cancer
  • Genitourinary Cancers
    • Kidney Cancer
    • Bladder Cancer
    • Prostate Cancer
  • Gynecologic Cancers
    • Endometrial Cancer
    • Ovarian Cancer
    • Cervical Cancer
  • Head & Neck Cancer
  • Hematologic Oncology
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • Myeloproliferative Neoplasms
  • Infection
    • Vaccines
  • Leukemia
  • Lung Cancer
    • Small Cell Lung Cancer (SCLC)
    • Non-Small Cell Lung Cancer (NSCLC)
  • Lymphoma
  • Neuroendocrine Tumors
  • Oncology
  • Pediatric Cancers
  • Psycho-Oncology
  • Radiation Oncology
  • Sarcoma
  • Screening
  • Skin Cancer & Melanoma
  • Surgery
  • Thyroid Cancer
Spotlight -
Psycho-Oncology|
Artificial Intelligence|
Radiation Oncology|
Surgery
Advertisement

Keith Dawson, DNP, MS

Advertisement

Articles by Keith Dawson, DNP, MS

Real-World Assessment of Patient Care and Practice Efficiency With the Introduction of Subcutaneous Rituximab

ByEsther Drill, DrPH,Annie Qiu, BA,Sheila Shapouri, PharmD, MS,Tu My To, PhD, MPH,Arliene Ravelo, MPH,Jake Schade, BA,Keith Dawson, DNP, MS,Matthew J. Matasar, MD
December 22nd 2021

Rituximab-subcutaneously is associated with significantly reduced chair time vs rituximab-intravenously in a US oncology setting. Widespread adoption would be expected to improve practice efficiency and patient access to care, and to reduce health care resource burden.

Advertisement

Latest Updated Articles

  • Real-World Assessment of Patient Care and Practice Efficiency With the Introduction of Subcutaneous Rituximab
    Real-World Assessment of Patient Care and Practice Efficiency With the Introduction of Subcutaneous Rituximab

    December 22nd 2021



Advertisement
Advertisement

Trending on CancerNetwork

1

Top 3 Insights on Locoregional Recurrence in Young-Onset Breast Cancer

2

Adult T-Cell Leukemia/Lymphoma and Epstein-Barr Virus–Positive DLBCL: A Rare Concomitant Association

3

FDA Delays Decision on Subcutaneous Isatuximab in Multiple Myeloma

4

This Week in Oncology: Real-World NSCLC Care and AACR 2026 Updates

5

Discussing Proper Utilization of BCMA Bispecifics in Early Relapse Multiple Myeloma

  • About
  • Advertise
  • CureToday.com
  • OncLive.com
  • OncNursingNews.com
  • TargetedOnc.com
  • Editorial
  • Contact
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Personal Information
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

Brand Logo

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us